trending Market Intelligence /marketintelligence/en/news-insights/trending/yqdojkdaxau2rttgvbn-va2 content esgSubNav
In This List

Aileron Therapeutics' chief medical, scientific officer becomes CEO

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Aileron Therapeutics' chief medical, scientific officer becomes CEO

Aileron Therapeutics Inc. appointed Manuel Aivado as president and CEO.

Aivado succeeds John Longenecker, who replaced Joseph Yanchik III on an interim basis after he resigned.

Aivado has been the senior vice president and chief medical and scientific officer of the biopharmaceutical company since 2012. He most recently designed and implemented the first-in-human trial of the company's experimental anti-tumor therapy ALRN-6924.